Staurosporine

製品コードS1421 別名:CGP 41251

Staurosporine化学構造

分子量(MW):466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

サイズ 価格(税別)  
JPY 44820.00

カスタマーフィードバック(3)

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

製品安全説明書

PKC阻害剤の選択性比較

生物活性

製品説明 Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
ターゲット
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外試験

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells NH3nU2lEgXSxdH;4bYPDqGG|c3H5 NFvaRZY1QCCq NUjWfXBFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVRmNTB4IN88UU4> MVuyNVM5QDF7MR?=
human colon cancer cell line (LoVo cells) MV\Qdo9tcW[ncnH0bY9vKGG|c3H5 MkXzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiClb3zvckBk[W6lZYKgZ4VtdCCuaX7lJEhNd1[xIHPlcIx{MSC3c3nu[{BOXFRiYYPzZZktKEmFNUC9NE4xODFizszNMi=> NXToVnJ2OTF3OUG1NFU>
human LoVo cells NVvJZlc3WHKxbHnm[ZJifGmxbjDhd5NigQ>? M2nYVFQ5KHSxIEeyJIg> MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyxVn:gZ4VtdHNiYX\0[ZIhPDhidH:gO|IhcHK|IHL5JG1VXCCjc4PhfS=> M{\YflIzOTh{OUK5
P19 cells M36xeGZ2dmO2aX;uJIF{e2G7 NFP0UmlKdmirYnn0bY9vKG:oIGDsZZRmdGW2LXTldol3\WRiZ4Lve5RpKG[jY4TvdkBz\WOncITvdkBqdiCSMUmgZ4VtdHNuIFnDOVA:OC5yMEKg{txONg>? M3m2dFE2PzdzNEG5
human BJ cells NUTLVFM6S3m2b4TvfIlkyqCjc4PhfS=> M3n3VFczKGh? NYD1R|A3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkpiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MD6wNFIh|ryPLh?= M3flSFIzQTJzMEix
human HT-29 cells MmfjSpVv[3Srb36gZZN{[Xl? MV2yJIg> MkG2SYZn\WO2IH;uJI1qfG:laH;u[JJq[WxibXXtZpJidmVicH;0[Y51cWGuIHnuJIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEKgbJJ{KHW|aX7nJGpENTFic4ThbY5qdmdiYomg[ox2d3Knc3PlcoNmKGG|c3H5 NXmz[nZXOjF2MkizO|U>
human A549 cells Ml:5R5l1d3SxeHnjxsBie3OjeR?= MVe3NkBp Mlq1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDt[ZRpd2R? NULDXXBFOTh2OES3O|U>
human HT-29 cells MmHPSpVv[3Srb36gZZN{[Xl? MoDKTY5pcWKrdHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBqdiCqdX3hckBJXC1{OTDj[YxteyC3c3nu[{BLSzFiZInlJJN1[WmwaX7nJIJ6KG[udX;y[ZNk\W6lZTDwcIF1\SC{ZXHk[ZIh[XO|YYmsJGlEPTB;Mj61JI5O NUXyZYZwOjF3MUOyPVM>
human HT-29 cells MW\GeY5kfGmxbjDhd5NigQ>? MWGyJIg> MYHJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiWLUK5JINmdGy|IHHzd4V{e2WmIILl[JVkfGmxbjDv[kBucXSxY3jvcoRzcWGuIH3lcYJz[W6nIIDveIVvfGmjbDDh[pRmeiB{IHjyd{BjgSC3c3nu[{BLSzFic4ThbY5qdmdiYomg[ox2d3Knc3PlcoNmKGOnbHytZoF{\WRiYYPzZZktKEWFNUC9Nk43KG6PLh?= M1rBR|IyQTd|MUCx
Sf9 cells NXXtfG0yTnWwY4Tpc44h[XO|YYm= NVXuc3d4UW6qaXLpeIlwdiCxZjDoeY1idiCVeXug[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF0{KG6PLh?= Mln5NVg5OjN5OES=
human HUVEC NYDlWo9MWHKxbHnm[ZJifGmxbjDhd5NigQ>? NGPC[Vk1QCC2bzC3NkBp MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiXVlXDJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[Xl? M4i2RVIzOTh{OUK5
P19 cells M{nB[mZ2dmO2aX;uJIF{e2G7 M4jjV2lvcGmkaYTpc44hd2ZiUILveIVqdiCNaX7hd4UhSSCrbjDQNVkh[2WubIOsJGlEPTB;NDDuUU4> NVPwXFJEOTV5N{G0NVk>
Sf9 cells NUjWe5BUTnWwY4Tpc44h[XO|YYm= MVTJcohq[mm2aX;uJI9nKGi3bXHuJGZ6diCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEGgcYlvKGK7IFXMTXNCKGmwIIDy[ZNmdmOnIH;mJFEhfW2xbD;MJGFVWA>? M4jWOlE4OzF3OEWz
Sf21 cells M{DaUGZ2dmO2aX;uJIF{e2G7 MmP0TY5pcWKrdHnvckBw\iCMQVuzJIV5eHKnc4Pl[EBqdiCVZkKxJINmdGy|LDDJR|UxRTZibl2u MoixNVcxQDhyNUm=
human colon carcinoma cell line HCT116 NH73N|BHfW6ldHnvckBie3OjeR?= NXviWFRtS2:wY3XueJJifGmxbjDy[ZF2cXKnZDDmc5Ih\3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxibHnu[UBJS1RzMU[sJGlEPTB;NjDuUU4> MmD0NVU2Ozd|NEW=
human ST486 cells M1Xp[nBzd2yrZnXyZZRqd25iYYPzZZk> NEW0SpM1QCC2bzC3NkBp NIPDeGJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPUOFg3KGOnbHzzJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PyCwTT6= MV6yNlE5Ojl{OR?=
human MDA-MB-231 cells MljGR5l1d3SxeHnjxsBie3OjeR?= MWm3NkBp M{j3XWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJibXX0bI9lNCCJSUWwQVcvOSCwTT6= NVHLdYh7OTh2OES3O|U>
P19 cells M37QSWZ2dmO2aX;uJIF{e2G7 MXPJcohq[mm2aX;uJI9nKEO7Y3zpck1l\XCnbnTlcpQhc2mwYYPlJFEhcW5iUEG5JINmdGy|LDDJR|UxRThibl2u NUHjO2J7OTV5N{G0NVk>
human DLD1 cells NIf4R|NRem:uaX\ldoF1cW:wIHHzd4F6 MXW0PE04OiCq Mn;JRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGTFSxJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9PUBvVS5? NEPxT5gzOjF6MkmyPS=>
insect cells NEjRfldHfW6ldHnvckBie3OjeR?= NXTJSFhTUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQbY0yKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMh[nliSGTSSkwhUUN3ME2xNEBvVS5? NEX2b3gyQTF5OUC3Oi=>
V79 MZ cells M2C1WmZ2dmO2aX;uJIF{e2G7 NVqyPFRrUW6qaXLpeIlwdiCxZjDoeY1idiCjbHTvd5Rmem:wZTDzfY51cGG|ZTDlfJBz\XO|ZXSgbY4hXjd7IF3aJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXzkc5N1\XKxbnWgd5lvfGinc3nzMEBKSzVyPUGxJI5ONg>? NHL1VHkzPDR{MkWxPS=>
P19 cells MofnSpVv[3Srb36gZZN{[Xl? NV;xTZg6UW6qaXLpeIlwdiCxZjDWZZNkfWyjcjDlcoRwfGinbHnhcEBoem:5dHig[oFkfG:{IILlZ4VxfG:{IHnuJHAyQSClZXzsd{whUUN3ME2xOEBvVS5? NInRT2UyPTd5MUSxPS=>
Sf9 cells M1LaOmZ2dmO2aX;uJIF{e2G7 MYKyNEBucW6| M2\vU2lvcGmkaYTpc44hd2ZiaIXtZY4hTnmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNlAhdWmwczDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGCsJGlEPTB;MUWgcm0v MUOxO|MyPTh3Mx?=
human PBMC M16xdmZ2dmO2aX;uJIF{e2G7 NWrKZ3N4OjRiaB?= MVvTeZBxemW|c3nvckBw\iCLTEKgdJJw\HWldHnvckBqdiCqdX3hckBRSk2FIHHmeIVzKDJ2IHjyd{BjgSCHTFnTRUwhUUN3ME2xOkBvVS5? M{nEOVE5PTh3MES2
human A549 cells NYnK[lNqS3m2b4TvfIlkyqCjc4PhfS=> M3HLdVQ5KGh? MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgMEBKSzVyPUKwJI5ONg>? M37L[|I2QDJ3OUO0
human CEM cells MlTTR5l1d3SxeHnjxsBie3OjeR?= MkDIO|IhcA>? MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPhcINmcW5iQV2gZZN{[XluIFnDOVA:OjNibl2u NXrKO4hJOjJ7MkGwPFE>
human HeLa cells NVLqUFhKS3m2b4TvfIlkyqCjc4PhfS=> MXi0PEBp MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MkWgcm0v MnezNlU5OjV7M{S=
human PC3 cells M3vCT2N6fG:2b4jpZ:Kh[XO|YYm= MVK0PEBp MmHNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgMEBKSzVyPUOxJI5ONg>? NFXoSWozPTh{NUmzOC=>
human SF268 cells NES4dFREgXSxdH;4bYPDqGG|c3H5 MnP3OFghcA>? MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTSlI3QCClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUS0JI5ONg>? MnTDNlE2OTN{OUS=
human MCF7 cells M3XIdWN6fG:2b4jpZ:Kh[XO|YYm= Mkj5OFghcA>? MofGR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUWwJI5ONg>? M4DpVVIyOzh6MUmx
HEK293 cells NWLvcIY3S3m2b4TvfIlkyqCjc4PhfS=> M1nGPFczKGh? NVPiflNGS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYLHcI8h[XO|YYmsJGlEPTB;NU[gcm0v NGX4bFQzPDd4M{K2Ni=>
HUE cells Ml:0SpVv[3Srb36gZZN{[Xl? MnTmPVAhdWmwcx?= M1q2NmlvcGmkaYTpc44hd2ZiVlXHSnIzKGmwIFjVSUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIG\FS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHS{ZXH0[YQh\m:{IEmwJI1qdnNiYnXmc5JmKF[HR1[gZ4hidGynbnflJIJ6KEWOSWPBMEBKSzVyPUewJI5ONg>? NYHaT5NCOjBzN{CxOlM>
human A431 cells MYrDfZRwfG:6aXRCpIF{e2G7 M3\UV|I1KCCq M3TYTGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh[W[2ZYKgNlQhcHK|IIXzbY5oKEGwbnX4bY4hXmWISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZpkhVVSWIHHzd4F6NCCLQ{WwQVcxKG6PLh?= M1XsTFIzPTRzMEWx
human Jurkat cells NWHuV4NlWHKxbHnm[ZJifGmxbjDhd5NigQ>? M2DKe2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgTmFMOyCneIDy[ZN{cW6pIFnMNk1{fGmvdXzheIVlKGi3bXHuJGp2emujdDDj[YxteyxiSVO1NF04OSCwTT6= NITSbGkyQTR{N{KwNy=>
HEK293 cells Mn3KSpVv[3Srb36gZZN{[Xl? M2LaSGlvcGmkaYTpc44hd2ZiSVytPEBz\WynYYPlJIJ6KEiHS{K5N{Bk\WyuczDlfJBz\XO|aX7nJHBMSy2kZYThNkwhUUN3ME23O{BvVS5? Mkj6NVU4PzF2MUm=
human KE-97 cells MmLMR5l1d3SxeHnjxsBie3OjeR?= NUSweYV6PzJiaB?= M17DeGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtGNTl5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTNizszNMi=> Mo\hNlQ{Ojh{OEO=
human CHOK1 cells NUTyXHRFS3m2b4TvfIlkyqCjc4PhfS=> M2PYXVQ5KGh? M1ix[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNJV0tzIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjF|IN88UU4> MV[yNVUyOzJ7NB?=
mouse NIH/3T3 cells MnHvR5l1d3SxeHnjxsBie3OjeR?= MVW5OkBp MmnFR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUmlJNzOWMzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u MVyyOFM3OTV{MR?=
human A2780 cells MkXrR5l1d3SxeHnjxsBie3OjeR?= M{jaWVk3KGh? NVfRdmt5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJizszNMi=> NFXYcHMzPDN4MUWyNS=>
human 8505C cells M2HwfGN6fG:2b4jpZ:Kh[XO|YYm= M2nSTFk3KGh? MknMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gPFUxPUNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= MkTTNlQ{PjF3MkG=
human 518A2 cells NXntfY5nS3m2b4TvfIlkyqCjc4PhfS=> M3v5Ulk3KGh? M2jx[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFUyQEF{IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjJizszNMi=> MYKyOFM3OTV{MR?=
human HuH7 cells M1r1UGN6fG:2b4jpZ:Kh[XO|YYm= MXu3NkBp NUfZeJlwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|IN88UU4> NYrFR2RLOjR|MkiyPFM>
FL5.12-Akt1 cells NUnDT|dkWHKxbHnm[ZJifGmxbjDhd5NigQ>? NVO2OVhYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBHVDVwMUKtRYt1OSClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5{OTFOwG0v NVfxdIROOTZ2MEO2NlY>
human MiaPaCa-2 cells M{H5OnBzd2yrZnXyZZRqd25iYYPzZZk> MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2rYWDhR4EuOiClZXzsd{whUUN3ME2wMlM4KM7:TT6= NUXV[mpCOTZ2MUO3PFA>
human BGC823 cells M3vVSWN6fG:2b4jpZ:Kh[XO|YYm= NGXGSZk4OiCq NWTBbldZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkeFOEKzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1emVvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{ig{txONg>? NIW2NmMzPDN{OEK4Ny=>
human MCF7 cells MWXDfZRwfG:6aXRCpIF{e2G7 NFSwZm46PiCq NGLjWndEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE41KM7:TT6= NFTFenUzPDN4MUWyNS=>
human A549 cells M4npN2N6fG:2b4jpZ:Kh[XO|YYm= NHLs[nY6PiCq MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD62JO69VS5? Mon6NlQ{PjF3MkG=
HEK293 cells MWDDfZRwfG:6aXRCpIF{e2G7 M1nzRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczygSWM2OD1{IN88UU4> M1P6XlI2OzF4M{G3
human Raji cells  NWrLN2VzS3m2b4TvfIlkyqCjc4PhfS=> M2LzW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJicmliY3XscJMtKEWFNUC9NkDPxE1w NWrUemc{OjV|MU[zNVc>
human HepG2 cells Mlr0R5l1d3SxeHnjxsBie3OjeR?= NYPzRmRkS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFXDOVA:OiEQvF2u MV6yOVMyPjNzNx?=
human BJ cells MlKyR5l1d3SxeHnjxsBie3OjeR?= Mmj6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOsJGVEPTB;MjFOwG0v NXzteodsOjV|MU[zNVc>
human U937 cells NW\BU5lXS3m2b4TvfIlkyqCjc4PhfS=> MlHqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVk{PyClZXzsd{whUUN3ME2yJO69VS5? NUnlR5JwOTdyOEiwOlc>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
細胞試験:

[3]

+ 展開
  • 細胞株: PC12
  • 濃度: Dissolved in DMSO, final concentration 1 μM
  • 反応時間: ~32 hours
  • 実験の流れ:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (参考用のみ)
動物試験:

[8]

+ 展開
  • 動物モデル: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~10 ng
  • 投与方法: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 466.53
化学式

C28H26N4O3

CAS No. 62996-74-1
保管
別名 CGP 41251

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

PKCシグナル伝達経路

相関PKC製品

Tags: Staurosporineを買う | Staurosporine ic50 | Staurosporine供給者 | Staurosporineを購入する | Staurosporine費用 | Staurosporine生産者 | オーダーStaurosporine | Staurosporine化学構造 | Staurosporine分子量 | Staurosporine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID